AI Chiefs and Biotech Leaders Unite to Demand Mandatory DNA Synthesis Screening Safeguards

AI Chiefs and Biotech Leaders Unite to Demand Mandatory DNA Synthesis Screening Safeguards

In a rare display of industry-wide consensus, the chief executives of the world's leading artificial intelligence laboratories have joined forces with life sciences researchers and national security experts to call for federal regulation of synthetic biology. On June 3, 2026, a public open letter urged U.S. lawmakers to implement mandatory screening and recordkeeping for synthetic DNA and RNA orders, warning that rapidly advancing AI models are eroding the technical barriers to creating dangerous bioweapons.¹

The letter was signed by major tech leaders—including Sam Altman (CEO of OpenAI), Dario Amodei (CEO of Anthropic), Demis Hassabis (CEO of Google DeepMind), and Mustafa Suleyman (CEO of Microsoft AI)—alongside prominent microbiologists, biosecurity experts, and executives from gene synthesis firms like Twist Bioscience and Ansa Biotechnologies. The effort was organized by the nonpartisan Institute for Progress (IFP) and the Foundation for American Innovation (FAI).

Erasing the Barriers to Bioweapons

The core concern driving the coalition is the speed at which frontier AI models are gaining biological reasoning capabilities. The letter points out that modern AI systems already outperform PhD-level virologists on technical, domain-specific laboratory procedures (such as those measured on specialized benchmarks like virologytest.ai). While the immediate threat level remains a subject of debate, the signatories warn that the unchecked intersection of automated gene synthesis and advanced AI poses severe risks.

If prompted effectively, advanced models can assist bad actors in designing lethal pathogens or circumventing existing screening software by suggesting structural variants of known toxins.

"AI systems now outperform PhD-level virologists on questions about highly technical laboratory procedures in their own domains of expertise. The evidence about what this means for present-day biosecurity threats is genuinely mixed, but the trend is hard to dispute. AI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode." — Open Letter: In Support of Mandatory Nucleic Acid Synthesis Screening and Recordkeeping

Proposed Regulatory Safeguards

To counter these emerging risks, the letter advocates for a standardized federal framework to replace voluntary industry guidelines:

• Mandatory Customer & Order Screening: Providers of synthetic DNA and DNA-printing equipment would be legally required to verify customer legitimacy and screen all orders for "sequences of concern."
• Comprehensive Recordkeeping: Companies must log all synthesis orders and sequence data. This ensures that even if a dangerous sequence slips past initial filters by being broken into separate, seemingly benign orders, investigators can trace the threat back to its source post-incident.

"Support for screening does not depend on any particular view of AI; the biosecurity case has been recognized by scientists and governments for decades. Screening is also one of the best understood and least disruptive biosecurity measures available." — Open Letter: In Support of Mandatory Nucleic Acid Synthesis Screening and Recordkeeping